Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women

Antimicrob Agents Chemother. 2007 Feb;51(2):783-6. doi: 10.1128/AAC.00420-06. Epub 2006 Dec 11.

Abstract

Human immunodeficiency virus-infected women (n=16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Cytochrome P-450 CYP3A / metabolism
  • Female
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors* / adverse effects
  • HIV Protease Inhibitors* / pharmacokinetics
  • HIV-1*
  • Humans
  • Indinavir* / adverse effects
  • Indinavir* / pharmacokinetics
  • Infant, Newborn
  • Liver / metabolism
  • Male
  • Maternal-Fetal Exchange
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*

Substances

  • HIV Protease Inhibitors
  • Indinavir
  • Cytochrome P-450 CYP3A